Peapack-Gladstone Financial Corp’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.81M Sell
24,292
-10
-0% -$1.5K 0.04% 273
2026
Q1
$3.71M Buy
24,302
+23
+0.1% +$3.53K 0.05% 268
2025
Q4
$3.35M Buy
24,279
+62
+0.3% +$8.12K 0.04% 286
2025
Q3
$3.1M Buy
24,217
+1,720
+8% +$210K 0.04% 290
2025
Q2
$2.72M Buy
22,497
+2,188
+11% +$247K 0.04% 296
2025
Q1
$2.26M Sell
20,309
-4,333
-18% -$461K 0.03% 319
2024
Q4
$2.4M Sell
24,642
-515
-2% -$54.9K 0.03% 301
2024
Q3
$2.9M Buy
25,157
+39
+0.2% +$4.42K 0.04% 294
2024
Q2
$2.67M Sell
25,118
-451
-2% -$45.3K 0.04% 293
2024
Q1
$2.47M Sell
25,569
-925
-3% -$94.8K 0.04% 298
2023
Q4
$2.67M Sell
26,494
-1,085
-4% -$105K 0.05% 278
2023
Q3
$2.81M Sell
27,579
-611
-2% -$62K 0.05% 256
2023
Q2
$2.84M Sell
28,190
-23
-0.1% -$2.3K 0.05% 262
2023
Q1
$2.59M Sell
28,213
-35,291
-56% -$3.08M 0.05% 274
2022
Q4
$5.76M Sell
63,504
-1,935
-3% -$163K 0.11% 192
2022
Q3
$4.97M Buy
65,439
+2,866
+5% +$238K 0.1% 194
2022
Q2
$5.29M Sell
62,573
-1,142
-2% -$100K 0.12% 173
2022
Q1
$5.59M Sell
63,715
-11,947
-16% -$1.03M 0.11% 178
2021
Q4
$6.62M Buy
75,662
+54
+0.1% +$4.48K 0.13% 164
2021
Q3
$6.18M Sell
75,608
-107
-0.1% -$9.63K 0.13% 166
2021
Q2
$6.91M Sell
75,715
-1,539
-2% -$137K 0.17% 136
2021
Q1
$6.6M Sell
77,254
-553
-0.7% -$49.6K 0.17% 135
2020
Q4
$7.35M Sell
77,807
-23,420
-23% -$2.05M 0.22% 116
2020
Q3
$8.8M Buy
101,227
+1,041
+1% +$90.2K 0.32% 89
2020
Q2
$8.75M Buy
100,186
+11,622
+13% +$1M 0.35% 82
2020
Q1
$7.3M Buy
88,564
+34,352
+63% +$3.06M 0.34% 84
2019
Q4
$5.13M Buy
54,212
+422
+0.8% +$37.9K 0.21% 111
2019
Q3
$4.67M Sell
53,790
-135
-0.3% -$12.1K 0.2% 107
2019
Q2
$4.92M Sell
53,925
-7,414
-12% -$627K 0.21% 110
2019
Q1
$5.29M Buy
61,339
+38
+0.1% +$3.05K 0.24% 103
2018
Q4
$4.71M Buy
61,301
+43,038
+236% +$3.35M 0.24% 102
2018
Q3
$1.41M Buy
18,263
+2,907
+19% +$215K 0.07% 166
2018
Q2
$1.04M Sell
15,356
-63
-0.4% -$4.35K 0.05% 179
2018
Q1
$1.12M Sell
15,419
-1,727
-10% -$131K 0.06% 174
2017
Q4
$1.29M Buy
17,146
+681
+4% +$51.4K 0.07% 163
2017
Q3
$1.27M Sell
16,465
-587
-3% -$44.3K 0.07% 159
2017
Q2
$1.28M Sell
17,052
-2,363
-12% -$167K 0.08% 157
2017
Q1
$1.29M Buy
19,415
+277
+1% +$18.5K 0.08% 155
2016
Q4
$1.25M Sell
19,138
-2,348
-11% -$152K 0.08% 152
2016
Q3
$1.52M Buy
21,486
+368
+2% +$26.8K 0.1% 144
2016
Q2
$1.56M Sell
21,118
-3,606
-15% -$249K 0.11% 141
2016
Q1
$1.6M Sell
24,724
-793
-3% -$53.9K 0.11% 139
2015
Q4
$1.97M Sell
25,517
-12
-0% -$953 0.14% 133
2015
Q3
$2.1M Sell
25,529
-1,076
-4% -$95.8K 0.16% 132
2015
Q2
$2.34M Sell
26,605
-380
-1% -$34.9K 0.16% 125
2015
Q1
$2.38M Buy
26,985
+223
+0.8% +$19.8K 0.16% 121
2014
Q4
$2.22M Sell
26,762
-1,545
-5% -$128K 0.16% 126
2014
Q3
$2.39M Sell
28,307
-1,086
-4% -$87.9K 0.18% 118
2014
Q2
$2.38M Buy
29,393
+575
+2% +$45.2K 0.18% 117
2014
Q1
$2.2M Sell
28,818
-111
-0.4% -$8.09K 0.17% 119
2013
Q4
$2.08M Sell
28,929
-607
-2% -$42.2K 0.17% 120
2013
Q3
$2.03M Sell
29,536
-1,045
-3% -$69.1K 0.18% 115
2013
Q2
$1.94M Buy
+30,581
New +$1.99M 0.18% 111

Other funds holding NVS

Peapack-Gladstone Financial Corp's NVS Position: Q2 2026 in Review

Peapack-Gladstone Financial Corp reduced its Novartis (NVS) stake by 0.04% in Q2 2026, selling an estimated $1.5K and leaving 24,292 shares worth $3.81M. The position accounts for 0.04% of the portfolio, ranked #273.

Peapack-Gladstone Financial Corp first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.8M in Q3 2020. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Peapack-Gladstone Financial Corp held 24,292 shares of Novartis worth $3.81M as of Q2 2026.
  • Peapack-Gladstone Financial Corp sold 10 Novartis shares in Q2 2026, an estimated $1.5K.
  • Novartis made up 0.04% of Peapack-Gladstone Financial Corp's portfolio in Q2 2026, its #273 holding.
  • Peapack-Gladstone Financial Corp first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Peapack-Gladstone Financial Corp's Novartis position peaked at $8.8M in Q3 2020.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q2 2026, filed 14 Aug 2026.